Drug intelligence / Profile preview

OJL332

Development stage: Preclinical
Lead developer: Bausch + Lomb
Modality: Small Molecules
Administration: Topical Ophthalmic

Overview

OJL332 is a second-generation, small molecule antagonist of the transient receptor potential vanilloid 1 (TRPV1) receptor, also known as the vanilloid receptor. It is in preclinical development as a potential therapy for ocular surface diseases, likely targeting chronic ocular surface pain or related indications. OJL332 was initially developed by Bausch & Lomb, later held by Novartis, and as of 2023 acquired by Bausch + Lomb.

Other names: OJL332OJL-332OJL 332

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on OJL332.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OJL332.

Explore the full profile